How Ethnicity Plays a Role in Personalised Medicine

Genetic Testing for Medication Efficacy

In the evolving landscape of personalised medicine, genetic testing for medication efficacy has emerged as a powerful tool in optimising treatment plans for various conditions. By understanding how an individual’s genetic makeup influences their response to medications, healthcare providers can tailor treatments to maximise effectiveness and minimise adverse effects. However, the efficacy and accuracy of these medications can vary significantly across different populations, primarily due to the differences in the availability and depth of research conducted on diverse ethnic groups.

The Promise of Genetic Testing in Medicine

Genetic testing in medicine focuses on identifying variations in genes that affect how a person responds to drugs as a result of how they absorb, distribute or metabolise in the system, and remove or excrete drugs from their system. These tests can reveal whether a patient is likely to benefit from a particular medication, what dosage might be most effective, and which drugs should be avoided to prevent severe side effects. This approach is particularly valuable in treating conditions such as cancer, cardiovascular diseases, and mental health disorders, where the wrong drug or dosage can lead to suboptimal outcomes or dangerous side effects.

Ethnicity and Genetic Variation

One of the key factors influencing the success of genetic testing is the genetic diversity within and between populations. Different ethnic groups can have distinct genetic variations, known as polymorphisms, which affect drug metabolism and response. These differences are why certain populations may be more prone to specific drug reactions or why a medication that works well in one ethnic group may be less effective in another.

For instance, the enzyme CYP2D6, which is involved in the metabolism of many drugs, including antidepressants and pain relievers, has multiple variants that are distributed differently across populations. Some variants result in ultra-rapid metabolism, while others cause poor metabolism of drugs. These variants are more prevalent in certain ethnic groups, influencing how individuals within these groups respond to certain medications.

Populations with Extensive Research

Research on pharmacogenomics has not been evenly distributed across all ethnicities, with some populations benefiting from more comprehensive studies than others. Here’s a look at the ethnic groups where the most research exists:

European Populations:

The majority of pharmacogenomic research has historically been conducted on populations of European descent. As a result, genetic testing panels are often more accurate and predictive for individuals from these backgrounds. Studies have extensively explored genetic variants like those in the CYP450 family, which affect the metabolism of a wide range of medications, including antidepressants, anticoagulants, and chemotherapy drugs.

East Asian Populations:

Significant research has also been conducted in East Asian populations, particularly in China, Japan, and Korea. For example, the variant allele CYP2C19*3, which leads to poor metabolism of drugs like clopidogrel (a blood thinner), is more prevalent in East Asians. As a result, genetic testing for this variant is particularly relevant and widely used in these populations to guide medication choice and dosage.

African Populations:

While research is expanding, there is still a relative paucity of pharmacogenomic data on African populations compared to European and East Asian groups. However, studies have highlighted the genetic diversity within African populations, with multiple distinct variants of genes like CYP2B6, which is involved in the metabolism of HIV treatments and some antidepressants. This diversity underscores the need for more targeted research in these populations to improve the efficacy of genetic testing.

South Asian Populations:

South Asians represent another group where pharmacogenomic research is growing. Specific genetic variants influencing drug metabolism, such as those affecting the metabolism of statins and anti-diabetic drugs, have been identified. However, the overall body of research remains smaller compared to European and East Asian populations, indicating a need for further studies.

Latino Populations:

Pharmacogenomic research in Latino populations has been less extensive, although there is a growing recognition of the need to address this gap. Latino populations are often genetically diverse, with a mix of European, Indigenous American, and African ancestry, leading to a wide range of genetic variations. Research has started to identify specific variants affecting drug metabolism in this group, but much more work is needed to ensure the effectiveness of genetic testing.

The Impact of Gaps on Pharmacogenomic Research

The uneven distribution of pharmacogenomic research across ethnicities has significant implications for the accuracy and utility of genetic testing. Tests that are designed based on data from predominantly European populations may not be as effective or relevant for individuals from other ethnic backgrounds. This can lead to suboptimal treatment, increased side effects, or even serious adverse reactions in underrepresented groups.

For example, certain genetic variants that are rare in European populations but common in African or Asian populations may not be included in standard genetic testing panels. As a result, individuals from these groups may not receive the most effective or safest medications based on the available testing panels for their genetic profile.

Moving Toward More Inclusive Research

To fully realise the potential of personalised medicine, it is crucial to conduct more pharmacogenomic research across diverse populations. This includes not only expanding studies in underrepresented groups but also ensuring that genetic testing panels are updated to reflect the findings from these studies. By doing so, healthcare providers can offer more accurate and effective treatment options to patients of all ethnic backgrounds.

In the meantime, patients and healthcare providers should be aware of the limitations of genetic testing and consider ethnicity as a factor when interpreting test results. As more inclusive research becomes available, the promise of personalised medicine will become a reality for all, regardless of their ethnic background.

Hungry for more information? Read about the Top 5 Psychiatric Medications Sensitive to Pharmacogenomic (PGx) Testing.

For PGx testing prices, head here.